Different immune correlates associated with tumor progression and regression: Implications for prevention and treatment of cancer

Cancer Immunology, Immunotherapy

Volumn 57, Issue 8, 2008, Pages 1125-1136

  Hamilton, Duane H ^a   Bretscher, Peter A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Antibody IgG isotypes; Cancer immunology and correlates of tumor progression regression; Immune deviation; Th1 Th2

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER THERAPY; CANCER TRANSPLANTATION; HELPER CELL; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR REGRESSION; TUMOR RESISTANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; CELL LINE, TUMOR; DISEASE PROGRESSION; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MICE; MICE, INBRED DBA; NEOPLASM REGRESSION, SPONTANEOUS; NEOPLASM TRANSPLANTATION; NEOPLASMS; TH1 CELLS; TH2 CELLS;

EID: 44249119443     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0442-9     Document Type: Article

References (53)

1. Assudani DP, Horton RB, Mathieu MG, McArdle SE, Rees RC (2007) The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. Cancer Immunol Immunother 56(1):70-80
2. Awwad M, North RJ (1989) Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 49(7):1649-1654
3. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108(3):804-811
4. Biddison WE, Palmer JC (1977) Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y. Proc Natl Acad Sci USA 74(1):329-333
5. Bogen B (1996) Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 26(11):2671-2679
6. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175-208
7. Bretscher PA, Ismail N, Menon JN, Power CA, Uzonna J, Wei G (2001) Vaccination against and treatment of tuberculosis, the leishmaniases and AIDS: perspectives from basic immunology and immunity to chronic intracellular infections. Cell Mol Life Sci 58(12-13):1879-1896
8. Bretscher PA, Wei G, Menon JN, H Bielefeldt-Ohmann (1992) Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 257(5069):539-542
9. Burnet F (1957) Cancer a biological approach. BMJ 1:841-847
10. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B (2005) Primary antitumor immune response mediated by CD4+ T cells. Immunity 22(3):371-383
11. De Plaen E, Lurquin C, Lethe B, van der Bruggen P, Brichard V, Renauld JC, Coulie P, Van Pel A, Boon T (1997) Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. Methods 12(2):125-142
12. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329-360
13. Ehrlich P (1909) Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 5:273
14. Gorelik E (1983) Concomitant tumor immunity and the resistance to a second tumor challenge. Adv Cancer Res 39:71-120
15. Hahn H, Kaufmann SH, Miller TE, Mackaness GB (1979) Peritoneal exudate T lymphocytes with specificity to sheep red blood cells. I. Production and characterization as to function and phenotype. Immunology 36(4):691-698
16. Hailu A, Menon JN, Berhe N, Gedamu L, Hassard TH, Kager PA, Olobo J, Bretscher PA (2001) Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure. J Infect Dis 184(1):112-115
17. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188(12):2357-2368
18. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3(11):999-1005
19. Klein G (1968) Tumor-specific transplantation antigens: G.H.A. Clowes Memorial Lecture. Cancer Res 28:625-635
20. Kuhn R, Rajewsky K, Muller W (1991) Generation and analysis of interleukin-4 deficient mice. Science 254(5032):707-710
21. Lagrange PH, Mackaness GB (1975) A stable form of delayed-type hypersensitivity. J Exp Med 141(1):82-96
22. Lagrange PH, Mackaness GB, Miller TE (1974) Influence of dose and route of antigen injection on the immunological induction of T cells. J Exp Med 139(3):528-542
23. Mackaness GB, Lagrange PH, Miller TE, Ishibashi T (1974) Feedback inhibition of specifically sensitized lymphocytes. J Exp Med 139(3):543-559
24. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181-273
25. Menon JN, Bretscher PA (1996) Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge. Eur J Immunol 26(1):243-249
26. Menon JN, Bretscher PA (1998) Parasite dose determines the Th1/Th2 nature of the response to Leishmania major independently of infection route and strain of host or parasite. Eur J Immunol 28(12):4020-4028
27. Mosmann TR, Coffman RL (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173
28. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, Ohta A (1999) Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190(5):617-627
29. North RJ (1985) Down-regulation of the antitumor immune response. Adv Cancer Res 45:1-43
30. North RJ (1986) Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J Exp Med 164(5):1652-1666
31. North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71(1):90-95
32. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59(13):3128-3133
33. Parish CR (1972) The relationship between humoral and cell-mediated immunity. Transplant Rev 13:35-66
34. Paul WE, J Ohara (1987) B-cell stimulatory factor-1/interleukin 4. Annu Rev Immunol 5:429-459
35. Power CA, Grand CL, Ismail N, Peters NC, Yurkowski DP, Bretscher PA (1999) A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFNgamma-producing T cells. J Immunol Methods 227(1-2):99-107
36. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296
37. Ramshaw IA, Bretscher PA, Parish CR (1976) Regulation of the immune response. I. Suppression of delayed-type hypersensitivity by T cells from mice expressing humoral immunity. Eur J Immunol 6(10):674-679
38. Ramshaw IA, Bretscher PA, Parish CR (1977a) Regulation of the immune response. II. Repressor T cells in cyclophosphamide-induced tolerant mice. Eur J Immunol 7(3):180-185
39. Ramshaw IA, McKenzie IF, Bretscher PA, Parish CR (1977b) Discrimination of suppressor T cells of humoral and cell-mediated immunity by anti-Ly and anti-Ia sera. Cell Immunol 31(2):364-369
40. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92(25):11810-3
41. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18-32
42. Salvin SB (1958) Occurrence of delayed hypersensitivity during the development of Arthus type hypersensitivity. J Exp Med 107(1):109-124
43. Severinson E, Fernandez C, Stavnezer J (1990) Induction of germ-line immunoglobulin heavy chain transcripts by mitogens and interleukins prior to switch recombination. Eur J Immunol 20(5):1079-1084
44. Sher A, Gazzinelli RT, Oswald IP, Clerici M, Kullberg M, Pearce EJ, Berzofsky JA, Mosmann TR, James SL, Morse HC 3rd (1992) Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev 127:183-204
45. Snapper CM, Peschel C, Paul WE (1988) IFN-gamma stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J Immunol 140(7):2121-2127
46. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H (1998) Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 95(3):1178-1183
47. Uyttenhove C, Maryanski J, Boon T (1983) Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 157(3):1040-1052
48. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9(10):1269-1274
49. Uzonna JE, Bretscher PA (2001) Anti-IL-4 antibody therapy causes regression of chronic lesions caused by medium-dose Leishmania major infection in BALB/c mice. Eur J Immunol 31(11):3175-3184
50. Uzonna JE, Wei G, Yurkowski D, Bretscher P (2001) Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol 167(12):6967-6974
51. Wolf ML, Weng WK, Stieglbauer KT, Shah N, LeBien TW (1993) Functional effect of IL-7-enhanced CD19 expression on human B cell precursors. J Immunol 151(1):138-148
52. Yamaguchi T, Sakaguchi S (2006) Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16(2):115-123
53. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6(4):295-307